IQVIA Holdings Inc. (IQV) is a global leader in analytics, technology, and clinical research for life sciences with a market cap of $32.2 billion. The company operates through four segments and is classified as a large-cap stock poised for growth despite recent stock dips.

Shares of IQVIA have declined 25.9% from its 52-week high, but have surged 15.1% in the past three months. The stock has been trading above its 50-day and 200-day moving averages, indicating an uptrend. On July 22, IQVIA shares jumped 17.9% following strong Q2 results.

IQVIA’s top rival, Agilent Technologies, Inc. (A), has fallen 7.6% YTD, lagging behind IQV. Despite recent drops, IQV has a consensus “Strong Buy” rating from analysts, with a mean price target of $213.52 suggesting a 16.1% potential increase from current prices.

Read more at Yahoo Finance: How Is IQVIA Holdings’ Stock Performance Compared to Other Health Tech Stocks?